CoChat

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Open access
Mateo, Joaquin, Ganji, Gopinath, Lemech, Charlotte, Burris, Howard A., Han, Sae-Won, Swales, Karen, Decordova, Shaun, DeYoung, M. Phillip, Smith, Deborah A., Kalyana-Sundaram, Shanker, Wu, Jiuhua, Motwani, Monica, Kumar, Rakesh, Tolson, Jerry M., Rha, Sun Young, Chung, Hyun Cheol, Eder, Joseph P., Sharma, Sunil, Bang, Yung-Jue, Infante, Jeffrey R., Yan, Li, de Bono, Johann S., Arkenau, Hendrik-Tobias · 2017 · Clinical Cancer Research
Cited by 145

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target effects of pan-PI3K inhibitors. GSK2636771 is a potent, orally bioavailable, adenosine triphosphate-competitive, selective inhibitor of PI3Kβ. Methods: We evaluated the safety, pharmacokinetics, pharmacodynamics and antitumor activity of GSK2636771 to define the recommended phase II dose (RP2D). During the dose-selection and dose-escalation stages (parts 1 and 2), patients with PTEN-deficient advanced solid tumors received escalating doses of GSK2636771 (25–500 mg once daily) using a modified 3+3 design to determine the RP2D; tumor type-specific expansion cohorts (part 3) were implemented to further assess tumor responses at the RP2D. Results: A total of 65 patients were enrolled; dose-limiting toxicities were hypophosphatemia and hypocalcemia. Adverse events included diarrhea (48%), nausea (40%), and vomiting (31%). Single- and repeat-dose exposure increased generally dose proportionally. GSK2636771 400 mg once daily was the RP2D. Phospho/total AKT ratio decreased with GSK2636771 in tumor and surrogate tissue. A castrate-resistant prostate cancer (CRPC) patient harboring PIK3CB amplification had a partial response for over a year; an additional 10 patients derived durable (≥24 weeks) clinical benefit, including two other patients with CRPC with PIK3CB alterations (≥34 weeks). GSK2636771 400 mg once daily orally induced sufficient exposure and target inhibition with a manageable safety profile. Conclusions: Genomic aberrations of PIK3CB may be associated with clinical benefit from GSK2636771. Clin Cancer Res; 23(19); 5981–92. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0725

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 145

Metadata

Authors
Mateo, J., Ganji, G., Lemech, C., Burris, H. A., Han, S.-W., Swales, K., Decordova, S., DeYoung, M. P., Smith, D. A., Kalyana-Sundaram, S., Wu, J., Motwani, M., Kumar, R., Tolson, J. M., Rha, S. Y., Chung, H. C., Eder, J. P., Sharma, S., Bang, Y.-J., Infante, J. R., Yan, L., de Bono, J. S., & Arkenau, H.-T.
Venue
Clinical Cancer Research
Published
2017-10-01
Volume
23
Issue
19
Pages
5981-5992
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2629851442
Cited by
145
References
9
FWCI
4.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0725
The paper
Mateo, J., Ganji, G., Lemech, C., Burris, H. A., Han, S.-W., Swales, K., Decordova, S., DeYoung, M. P., Smith, D. A., Kalyana-Sundaram, S., Wu, J., Motwani, M., Kumar, R., Tolson, J. M., Rha, S. Y., Chung, H. C., Eder, J. P., Sharma, S., Bang, Y.-J., . . . Arkenau, H.-T. (2017). A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0725

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.